Company intelligence / Profile preview

Epitel

Salt Lake City, Utah, United Statesepitel.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

The company’s REMI system received FDA clearance in 2021. It enables rapid, wireless, wearable EEG monitoring for seizure detection in hospitals and ambulatory settings. Clinical results have demonstrated the system’s ability to provide accessible, high-fidelity brain wave data to support diagnosis and management of seizures.

Therapeutic areas: Neurology
Modalities: Device (wearable EEG sensor)AI-enabled software platform
Industry: Physiological Monitoring

Partnerships

OSF HealthCare (strategic funding partnership)

Beyond the preview

Go deeper on Epitel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epitel.

Explore the full profile